GSK864 is primarily utilized in research settings as a selective inhibitor of the enzyme p300/CBP-associated factor (PCAF), which plays a significant role in regulating gene expression through histone acetylation. Its application is crucial in studying the mechanisms of epigenetic regulation and its impact on various cellular processes, including cell differentiation, proliferation, and apoptosis. Researchers employ GSK864 to investigate the role of PCAF in diseases such as cancer, where aberrant histone acetylation is often observed. By inhibiting PCAF, GSK864 helps elucidate potential therapeutic targets and pathways for treating conditions linked to epigenetic dysregulation. Additionally, it is used in drug discovery to evaluate the efficacy of epigenetic modulators in preclinical models.